High-affinity human monoclonal antibody against yellow fever virus and application thereof

An antibody and sequence technology, applied in the field of medicine, can solve the problems of lack of specific drugs, shortages, frequent outbreaks of diseases, etc.

Active Publication Date: 2019-10-18
INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, an attenuated vaccine (YFV17D) is clinically available, but the shortage of vaccine and insufficient vaccination rate lead to frequent outbreaks of the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High-affinity human monoclonal antibody against yellow fever virus and application thereof
  • High-affinity human monoclonal antibody against yellow fever virus and application thereof
  • High-affinity human monoclonal antibody against yellow fever virus and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1: Expression and purification of yellow fever virus E protein

[0032] YFV CNYF01 / 2016 (YFV-China) strain membrane protein E protein (amino acid sequence shown in SEQ ID NO: 11, nucleotide sequence shown in SEQ ID NO: 12) extracellular region DNA fragment by NdeI and XhoI enzymes After cutting, it was connected to the pET21a vector. The 3' end of the YFV E protein coding region is connected with the coding sequence of 6 histidine tags (hexa-His-tag) and the translation stop codon. Then the ligation product was transformed into BL21 Escherichia coli competent cells. Single clones were inoculated into 40mL LB medium and cultured for 6-8 hours. Inoculate into 4L of LB medium, culture at 37°C until OD600=0.4-0.6, add IPTG to a final concentration of 1 mM, and continue culturing at 37°C for 4-6 hours. Inclusion bodies were harvested and refolded by dilution. After the refolding solution was concentrated, it was replaced with 20mM Tris, 150mM NaCl, pH8.0 buffe...

Embodiment 2

[0033] Example 2: Isolation of specific memory B cells combined with YFV China-E protein

[0034] With the patient's informed consent, 20 mL of blood was collected and PBMCs were isolated. Separated PBMCs in 10 7 / mL density and final concentration of 400nM YFV-E protein was incubated on ice for half an hour, then washed twice with PBS, and then incubated with the following antibodies: anti-human CD3 / PE-Cy5, anti-human CD16 / PE- Cy5, anti-human CD235a / PE-Cy5, anti-human CD19 / APC-Cy7, anti-human CD27 / Pacific Blue, anti-human CD38 / APC, anti-human IgG / FITC, and anti-His / PE. After the antibody was incubated on ice for half an hour, it was washed twice with PBS.

[0035] Collect PE-Cy5 by FACSAria III sorting - APCs - APC-Cy7 + Pacific Blue +FITC + PE + The cells were directly collected into a 96-well plate, 1 cell / well.

Embodiment 3

[0036] Example 3: Single B cell PCR, sequence analysis and human antibody design

[0037] The B cells obtained in Example 2 were reverse-transcribed with Superscript III reverse transcriptase (Invitrogen), and the reverse transcription primers are shown in Table 1 (sequences are shown in SED ID NO.13 to SED ID NO.20), and reacted at 55° C. for 60 min.

[0038] Table 1. Primers for reverse transcription reactions

[0039]

[0040] Using this reverse transcription product as a template, PCR was performed with HotStar Tap Plus enzyme (QIAgen) to amplify the antibody variable region sequence (PCRa). The corresponding primers were designed, and the reaction conditions were as follows: 95°C, 5min; 95°C for 30s, 55°C (heavy chain / κ chain) / 50°C (λ chain) for 30s, 72°C for 90s, 35 cycles; 72°C, 7min. Use this as a template for the second round of PCR (PCRb), the conditions are as follows: 95°C, 5min; 95°C for 30s, 58°C (heavy chain) / 60°C (κ chain) / 64°C (λ chain) for 30s, 72°C 90s,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Affinityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a high-affinity human monoclonal antibody against yellow fever virus and application thereof, and belongs to the technical field of medicines. The high-affinity human monoclonal antibody against yellow fever virus is prepared by the following steps: taking E protein of yellow fever virus expressed in Escherichia coli as an antigen; screening memory B cells which can specifically bind to the E protein of yellow fever virus from PBMCs of a convalescent patient by performing flow sorting, thereby further obtaining variable-region fragments of an antibody; connecting the variable-region fragments of the antibody with a constant region to an expression vector; carrying out expression in mammalian cells, and carrying out purification; and then, carrying out a series of function tests, thereby obtaining 1 strain of the high-affinity human monoclonal antibody against yellow fever virus. The affinity between the antibody and the antigen is 1.49pm; moreover, the antibodyhas very strong yellow fever virus neutralization activity and IC50 at 4ng/ml. In addition, the antibody is capable of completely protecting mice from yellow fever virus at lethal dose. Thus, the high-affinity human monoclonal antibody against yellow fever virus has application values in clinical treatment and prevention of yellow fever virus.

Description

technical field [0001] The invention relates to a high-affinity yellow fever virus human monoclonal antibody and application thereof, belonging to the technical field of medicine. Background technique [0002] Yellow fever virus (yellow fever virus, YFV), a single-stranded positive-sense RNA virus, belongs to the Flaviviridae family and is a mosquito-borne pathogen that can cause human disease. The same family of viruses also includes Zika virus ( zikavirus, ZIKV), dengue virus (dengue virus, DENV), West Nile virus (west nile virus, WNV), etc. YFV is an important pathogen that causes yellow fever. In severe cases, it can cause hemorrhagic fever with multiple organ failure, especially the liver, spleen, lymph nodes, heart, and kidneys. [0003] In 1996, scientists estimated that yellow fever virus causes 200,000 infections and 300,000 deaths each year in Africa and South America. In the past two years, yellow fever outbreaks have occurred in places such as Brazil, Angola, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/10C12N15/13G01N33/569A61K39/42A61P31/14
CPCA61K2039/505A61P31/14C07K16/1081C07K2317/24C07K2317/76C07K2317/92G01N33/56983G01N2333/185Y02A50/30
Inventor 严景华高福李燕马素芳仵丽丽
Owner INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products